PARIS and BOSTON, April 14, 2015 (GLOBE NEWSWIRE) -- NEOVACS (Alternext Paris: ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, announced today that is has been selected to present at the seventh annual ChinaBio® Partnering Forum 2015 to be held in Shanghai, April 15 and 16, 2015.
This life science industry event is expected to attract over 800 attendees from around the world focused on partnering opportunities and cross-border relationships in China.
Miguel Sieler, CEO of Neovacs, will present recent information on Neovacs' proprietary active immunotherapy platform on April 15, 2015 at 2:30 pm CST (China Standard Time). China has a high prevalence of Systemic Lupus Erythematosus (SLE) or lupus, an autoimmune disease characterized by a significant unmet medical need. Several Chinese pharmaceutical companies have shown interest in the potential for an innovative, affordable biological treatment option, such as Neovacs' lead product candidate, IFNα-Kinoid.
About ChinaBio® Partnering Forum
ChinaBio® Partnering Forum is the premier life science partnering event in China. Held on April 15–16, 2015, in Shanghai, the event will attract over 800 biotech and pharma leaders from around the world along with hundreds of China-based developers of novel technologies for two days of productive partnering. There will also be over 30 speakers and 50 companies participating in panels and workshops as well as one-to-one partnering meetings held throughout the event.
Created in 1993, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company's proprietary technology for inducing a polyclonal immune response (covered by five patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFNα-Kinoid, an immunotherapy being developed for the indication of lupus. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology and allergies. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases.
For more information on Neovacs, please visit www.neovacs.fr.
CONTACT: ChinaBio(R) Group Jean Meng China: +86 21 5137 0751 USA: +1 858 926 4566 firstname.lastname@example.org NEOVACS - Investor Relations Nathalie Trepo +33 (0)1 53 10 93 00 email@example.com Investor Relations / Financial Communications - NewCap Valentine Brouchot / Pierre Laurent +33 (0)1 44 71 94 94 firstname.lastname@example.org Investor Relations / Financial Communications Germany - MC Services Raimund Gabriel +49-89-210228-30 email@example.com Press / U.S. Inquiries - The Ruth Group Melanie Sollid-Penton 1.646.536.7023 firstname.lastname@example.org